Fosrenol (lanthanum carbonate) / Takeda - LARVOL DELTA

Gastric Lanthanum Deposition in Advanced CKD: An Underrecognized Diagnostic Pitfall in Refractory Anemia and Mucosal Injury. (PubMed, Int J Nephrol) - "Lanthanum carbonate is a noncalcium phosphate binder used in advanced chronic kidney disease (CKD), especially in dialysis populations...Deposition alone does not establish causality, and the true prevalence of clinically meaningful disease remains unknown. Nevertheless, in selected patients with advanced CKD and refractory anemia, deliberate review of current and prior phosphate-binder exposure, appropriate gastric biopsy even when endoscopy is nondiagnostic, and reassessment after discontinuation may reveal a potentially reversible diagnostic contributor."

Journal • Review • Anemia • Chronic Kidney Disease • Hematological Disorders • Nephrology • Renal Disease

LaCa: Lanthanum Carbonate (Fosrenol) to Reduce Oxalate Excretion in Patients With Secondary Hyperoxaluria and Nephrolithiasis (clinicaltrials.gov) - P3 | N=54 | Completed | Sponsor: Universitair Ziekenhuis Brussel | Recruiting ➔ Completed | N=35 ➔ 54

Enrollment change • Trial completion • Nephrology • Renal Calculi

Lanthanum Carbonate Nanosheets Based Colloidal Hydrogel for Modulating Innate & Adaptive Tumor Immunotherapy by Augmented Cellular Pyroptosis. (PubMed, Adv Sci (Weinh)) - "This study elucidated that a colloidal hydrogel (GDLC hydrogel) loaded with decitabine (DAC) and crosslinked with lanthanum carbonate nanosheets (LCNSs) and gelatin nanoparticles (Gela NPs) could instigate pyroptosis in TNBC cells, specifically 4T1 cells. This strategy significantly curtailed tumor recurrence and metastasis, consequently improving the survival rates of mice in the 4T1 tumor-bearing mouse model. In conclusion, this colloidal hydrogel platform introduced an innovative paradigm for the immunotherapy of triple-negative breast cancer."

IO biomarker • Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CASP3 • GSDME

Correcting serum phosphate homeostasis does not alleviate the health dangers of high phosphate consumption. (PubMed, J Transl Med) - "This work advances the understanding of the health impacts of Pi additives which are common in ultra-processed foods and common in the Western style diet. Specifically, the results produce clinically relevant findings that simply controlling serum Pi and/or Ca levels or Pi responsive endocrine factors such as FGF23, PTH, and osteopontin are not sufficient to block the negative impacts of chronic high dietary Pi consumption on the skeleton. Further, therapeutic strategies to control serum Pi have an impact on the kidneys in the context of high dietary Pi intake."

Journal • Inflammation • Nephrology • Orthopedics • Osteoporosis • Renal Disease • FGF23 • SPP1

Novel therapeutic approaches for phosphate regulation. (PubMed, Curr Opin Nephrol Hypertens) - "Combining phosphate binders with agents that inhibit paracellular and transcellular intestinal phosphate absorption may improve the treatment of hyperphosphatemia while reducing pill burden in CKD. Defining optimal serum phosphate targets and the mortality benefits of phosphate lowering is essential to minimize treatment-related adverse effects."

Journal • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Lanthanum carbonate does not reduce urinary oxalate excretion in hyperoxaluric kidney stone formers. (PubMed, Nephrol Dial Transplant) - "Short-term treatment with LaCa at doses up to 1500 mg did not reduce urinary oxalate excretion in stone formers with idiopathic hyperoxaluria. Urinary phosphate excretion decreased without effect on serum phosphate."

Journal • Nephrology • Renal Calculi

Study on the Process and Mechanism of Preparing Lanthanum Carbonate from Rare Earth Chloride Solution. (PubMed, Materials (Basel)) - "Mechanistic studies suggest that this method effectively regulates the crystallization process by precisely controlling the introduction and slow dissolution of the La(OH)3 precursor, thereby reducing the supersaturation of the system during carbonation and facilitating the dissolution-reprecipitation of La3+. This work provides a theoretical basis for the preparation of high-quality rare earth carbonates and a process reference for the green recycling route."

Journal

Constructing a composite catalyst containing amorphous nickel hydroxide and crystalline lanthanum carbonate hydroxide for urea electrolysis. (PubMed, Nanoscale) - "Therefore, the assembled two-electrode system for urea-assisted water electrolysis only required a cell voltage of 1.42 V to achieve a current density of 10 mA cm-2, which was significantly superior to that of overall water electrolysis. This work provides a new idea for exploring metal carbonate hydroxides with high activity as stable electrocatalysts for water splitting and other organic electro-oxidation reactions."

Journal

ACID-SUPPRESSIVE AGENT USE AND PHOSPHATE BINDER PATTERNS IN PATIENTS UNDERGOING HEMODIALYSIS: RESULTS FROM THE MBD-NEXT (ISN-WCN 2026) - "Introduction Acid-suppressive agents, including proton pump inhibitors and histamine-2 receptor antagonists, can reduce the phosphate-binding efficacy of acid-dependent phosphate binders such as calcium carbonate and lanthanum carbonate...TH has received personal fees from Kissei Pharmaceutical and KKC, and grants from KKC. The remaining author has nothing to disclose.I did not use generative AI and AI-assisted technologies in the writing process."

Clinical • Orthopedics • Renal Disease

REGRESSION OF UREMIC TUMORAL CALCINOSIS FOLLOWING ETELCALCETIDE THERAPY IN HEMODIALYSIS PATIENTS (ISN-WCN 2026) - "At that time, he was receiving cinacalcet hydrochloride and lanthanum carbonate.Results We considered his intact PTH level was potentially underestimated, because blood sampling had been performed several hours after cinacalcet administration. Etelcalcetide has been reported to produce more sustained reductions in serum calcium and PTH levels than cinacalcet in hemodialysis patients, and this pharmacological property may contribute to the dissolution of calcified deposits. Our experience suggests that intravenous etelcalcetide therapy could represent a valuable therapeutic option for uremic tumoral calcinosis in selected patients, potentially expanding current management strategies beyond conventional approaches focused solely on calcium-phosphate control."

Clinical • Endocrine Disorders • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Oncology • Orthopedics • Renal Disease

Amyloid/Lanthanum-Based Hybrid Membrane for Removal of Uremic Toxins. (PubMed, Small) - "This study employs a one-step immersion technique, lanthanum carbonate-loaded protein/polysaccharide aggregates are attached to commercial ultrafiltration membranes via self-assembly, successfully producing dialysis membranes with a hierarchical surface structure...Furthermore, the composite membrane exhibits exceptional biocompatibility and resistance to protein adsorption. This study offers an innovative and scalable methodology for the development of next-generation portable artificial kidneys, presenting extensive potential for future applications."

Journal

Phytase-mimetic sulfated lanthanum oxycarbonate nanorods: A potential alternative for degrading phytic acid and enhancing nutrient bioavailability in cereal-based feeds. (PubMed, Int J Biol Macromol) - "Furthermore, in vitro digestion confirmed the efficacy of SLOC-NRs in degrading phytic acid under controlled conditions. These results suggest that SLOC-NRs could serve as a viable alternative to native enzymes, significantly enhancing the nutritional quality of cereal-based feeds and improving mineral bioavailability in monogastric diets."

Journal

Phosphate binders suppress glutaminase activity for treatment of cirrhosis and hepatic encephalopathy murine models. (PubMed, Biochem Pharmacol) - "The pharmacology and pharmacodynamics of Pi binders (sevelamer and lanthanum carbonate) were evaluated in CCl4-induced cirrhosis and both type A and C HE murine models...They had better therapeutic effects than L-ornithine L-aspartate (OA). Pi deprivation weakened glutaminase enzymatic activity, lowering collagen and Alpha-smooth muscle actin (α-SMA) production in HSCs and ammonia production in both wild-type and GLS1-overexpressing IECs. Since Pi deprivation alleviates glutaminolysis and ammonia production by decreasing glutaminase activity, Pi binders might hold great promising to treat cirrhosis and HE."

Journal • Preclinical • CNS Disorders • Fibrosis • Hepatic Encephalopathy • Hepatology • Immunology • Liver Failure • GLS1

Short-term lanthanum carbonate reduces calcification of cryopreserved aortic allografts in the young: A Porcine circulatory transplant model. (PubMed, Gen Thorac Cardiovasc Surg) - "Our results suggest that short-term lanthanum carbonate administration may alleviate cryopreserved allograft calcification in young recipients, without adverse effects."

Journal • Preclinical • Inflammation • Metabolic Disorders • Nephrology • Pediatrics • Transplantation

Association Between Serum 25-Hydroxyvitamin D and Bone Metabolism in Patients on Hemodialysis: Tokai Dialysis Cohort Study (KIDNEY WEEK 2025) - "Patients with higher serum 25(OH)D levels were more likely to be female; were less likely to have diabetes, a history of cerebral infarction, or peripheral arterial disease; had higher serum albumin and creatinine levels; and were more frequently prescribed lanthanum carbonate and active vitamin D. There was no association between 25(OH)D levels and serum calcium, phosphorus, or intact parathyroid hormone (PTH) levels...These findings suggest that vitamin D deficiency has at most a limited impact on bone metabolism in patients undergoing hemodialysis. Further studies are needed to clarify the role of 25(OH)D in bone metabolism in kidney failure."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Diabetes • Diabetic Nephropathy • Metabolic Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Peripheral Arterial Disease • Renal Disease

Oxylanthanum Carbonate Achieves Serum Phosphate Control with Significantly Lower Pill Burden in Patients with Hyperphosphatemia on Dialysis (KIDNEY WEEK 2025) - "Pretrial PB included sevelamer carbonate, calcium acetate, ferric citrate, and sucroferric oxyhydroxide. Combined with previously presented safety data, these findings suggest that OLC is safe, effective, and well-tolerated. Its small, easy-to-swallow formulation may be a welcome choice for pts with HP."

Clinical • Chronic Kidney Disease • Metabolic Disorders • Nephrology • Renal Disease

Comparative Phosphate-Lowering Effects of Tenapanor in Combination with Different Phosphate Binders in Patients on Hemodialysis: A Prospective Pilot Study (KIDNEY WEEK 2025) - "Methods In this prospective study, 55 HD patients were stratified into five groups based on their baseline phosphate binder (PB) use: PB-naïve, calcium-based binders, iron-based binders (ferric citrate), lanthanum carbonate, and polymer-based binders. Although the exact mechanism remains unclear, it is hypothesized that iron-based binders such as ferric citrate may alter intestinal pH—potentially affecting the local action of tenapanor. These preliminary results highlight the importance of binder selection in maximizing tenapanor efficacy and warrant further mechanistic and clinical studies."

Clinical • Combination therapy • Cardiovascular • Metabolic Disorders • Nephrology • Renal Disease

Lanthanum Carbonate-Induced Gastritis Presenting with Melena in a Patient with End Stage Renal Disease (ACG 2025) - "A trial of omeprazole twice daily provides no relief. In patients with unexplained upper GI symptoms or melena on lanthanum therapy, it is important to consider biopsy even in the setting of normal endoscopy. Discontinuation of lanthanum carbonate and switching to alternative binders often leads to symptom resolution."

Clinical • Anemia • Chronic Kidney Disease • Endocrine Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Inflammation • Metabolic Disorders • Nephrology • Renal Disease • Secondary Hyperparathyroidism

Crystalline Colitis: A Rare Adverse Effect of Sevelamer Therapy (ACG 2025) - "Home medications included sevelamer carbonate dosed at 2400mg three times daily...Given the presence of sevelamer crystals, the medication was discontinued and replaced with lanthanum carbonate. Sevelamer-induced colitis should be considered in dialysis patients presenting with unexplained colitis, especially when infectious and ischemic causes have been ruled out...Delayed recognition may lead to unnecessary treatments, prolonged symptoms, and increased morbidity. Early identification and discontinuation of sevelamer, with substitution by an alternative phosphate binder, are essential for symptom resolution and prevention of further gastrointestinal injury.Figure: Images A, B, C: Diffuse, severe inflammation found in the proximal transverse colon during colonoscopy."

Adverse events • Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Nephrology • Renal Disease

Whitish Deposits in the Stomach and Duodenum. (PubMed, United European Gastroenterol J) - No abstract available

Journal

Lanthanum carbonate lowers serum phosphorus without altering body phosphorus burden in maintenance peritoneal dialysis patients: a randomized crossover trial. (PubMed, Am J Clin Nutr) - P=N/A | "La2(CO3)3 treatment lowered serum phosphorus concentration but did not change body phosphorus content. This trial was registered at clinicaltrials.gov as NCT01581996."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease

Colorimetric Detection of Platinum (IV) Using 4-MethylSulfonylaniline-Modified Gold Nanoparticles in Lanthanum Carbonate API. (PubMed, Sensors (Basel)) - "Under optimal conditions, LOD and LOQ values of 10.00 × 10-3 μM and 3.03 × 10-2 μM, respectively, were observed. This method has been successfully applied to the determination of platinum (IV) in lanthanum carbonate API."

Journal

Hierarchically cactus-like nickel sulfide-lanthanum carbonate hydroxide composite for urea-assisted water splitting. (PubMed, J Chem Phys) - "Assembling NiSx-LaCH/NF into urea electrolysis system can reduce the cell voltage by 0.22 V compared to water electrolysis. This indicates that using UOR instead of OER could achieve energy-saving hydrogen production and has promising prospects in treating urea-rich wastewater."

Journal

A Phase 2 Clinical Trial of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia. (PubMed, Clin J Am Soc Nephrol) - "In this open-label Phase 2 trial, OLC was well tolerated and enabled sP control in >90% of patients with a low pill burden (two-thirds of patients receiving three or fewer tablets/day)."

Journal • P2 data • Metabolic Disorders • Nephrology • Renal Disease

A Case of Intestinal Granular Calcifications Associated With Phosphate Binder Use in a Patient on Hemodialysis. (PubMed, Clin Case Rep) - "An experienced physician correctly identified a high-intensity intestinal X-ray from Lanthanum Carbonate, preventing unnecessary tests and enabling proper treatment. Awareness of this is vital in managing renal failure patients."

Journal • Metabolic Disorders • Nephrology • Renal Disease